14 January
2025
Graft Polymer (UK)
plc
("Graft Polymer" or the "Company")
Announcement of Change of
Name to Solvonis Therapeutics plc
Graft Polymer (LON:GPL), an
innovative biotechnology company co-developing therapeutics for
mental health disorders, is pleased to announce the Company has
changed its name to Solvonis
Therapeutics plc.
A Certificate of Incorporation
reflecting the change of name has been issued by Companies House.
This change of name, along with the new TIDM of SVNS, will take
effect on the Main Market of the London Stock Exchange at 8:00 a.m.
on 15 January 2025.
The ISIN and SEDOL numbers for the
Company's ordinary shares will remain unchanged as GB00BMD1Z199 and
BMD1Z19, respectively.
Impact on Shareholders
There will be no impact on
shareholders as a result of this name change. Existing share
certificates will remain valid, and no action is required from
shareholders.
New
Website and Branding
As part of the rebranding, the
Company's website address will change to www.solvonis.com
in due course. The new name, Solvonis Therapeutics
plc, reflects the Company's evolving mission to develop novel
therapeutics for mental health and substance use
disorders.
Anthony Tennyson, CEO,
commented: "The name Solvonis Therapeutics is derived from the
Latin root solv, meaning
'to release, unbind, and free.' This change symbolizes our
commitment to freeing individuals from the constraints of mental
health and substance use disorders through innovative therapeutic
solutions."
"Solvonis Therapeutics plc's new
name and direction align with our core mission to improve the lives
of those suffering from mental health and addiction conditions,
particularly focusing on developing novel treatments that empower
patients to regain control of their lives."
Enquiries:
Graft Polymer (UK) plc / Solvonis Therapeutics
plc
Anthony Tennyson, CEO & Executive Director
Email: anthonytennyson@graftpolymer.co.uk and also
anthony@solvonis.com
Allenby Capital (Financial Adviser and
Broker)
Tel: +44 (0) 20 3328 5656
Nick Naylor / Liz Kirchner (Corporate Finance)
Guy McDougall (Sales)
About Graft Polymer / Solvonis Therapeutics
plc
Graft Polymer, now transitioning to
Solvonis Therapeutics plc, is an innovative biotechnology company
focused on developing intellectual property related to the
treatment of mental health and substance use disorders, and
co-developing therapeutics for these conditions. Our mission is to
improve outcomes for individuals suffering from these disorders,
with an initial focus on trauma-related mental health conditions,
such as PTSD. PTSD affected approximately 13 million adults in the
U.S. in 2020, with the Company estimating a current affected
population of 20 million across the U.S., UK, and key EU
markets.
For more information, please visit
www.graft polymer.co.uk and also www.solvonis.com